Cargando…

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients

INTRODUCTION: One of the remaining barriers to reaching WHO elimination targets of achieving global hepatitis C (HCV) cure is a lack of an established lower limit of detection (LLOD) to confirm cure post-treatment in near-patient technologies. Determining a LLOD at virologic failure aids in increasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Jake R., Savinkina, Alexandra, Pires dos Santos, Ana Gabriela, Xue, Zhenyi, Shilton, Sonjelle, Linas, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932931/ https://www.ncbi.nlm.nih.gov/pubmed/33590445 http://dx.doi.org/10.1007/s12325-021-01647-4

Ejemplares similares

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
por: Liu, Rujiao, et al.
Publicado: (2016)

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
por: Morgan, Jake R., et al.
Publicado: (2022)

Vitamin D(3) Supplementation: Comparison of 1000 IU and 2000 IU Dose in Healthy Individuals
por: Dědečková, Eva, et al.
Publicado: (2023)

A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
por: Saini, Vikas, et al.
Publicado: (2018)

2224. Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status
por: Cartwright, Emily J, et al.
Publicado: (2018)

Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort
por: Con, Danny, et al.
Publicado: (2019)

Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)

Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
por: Cabré, Francesc, et al.
Publicado: (2023)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
por: Pellicelli, Adriano M, et al.
Publicado: (2012)

Anticoagulant properties of enoxaparin 400 IU/mL–40 % ethanol catheter lock solution
por: Calvet, Laure, et al.
Publicado: (2015)

Arthroplasty studies with greater than 1000 participants: analysis of follow-up methods
por: Tariq, Muhammad B., et al.
Publicado: (2019)

HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
por: Xie, Yandi, et al.
Publicado: (2021)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis
por: Kuwano, Toru, et al.
Publicado: (2018)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
por: Struble, Kimberly, et al.
Publicado: (2019)

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
por: Menzella, Francesco, et al.
Publicado: (2023)

Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial
por: Sabico, Shaun, et al.
Publicado: (2021)

Liver Remodeling on CT Examination in Patients with HCV Compensated Cirrhosis Who Achieved Sustained Virological Response after Direct-Acting Antivirals Treatment
por: Mihai, Florin, et al.
Publicado: (2020)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding
por: Hughes, Steven D, et al.
Publicado: (2009)

Economic evaluation of HCV testing approaches in low and middle income countries
por: Morgan, Jake R., et al.
Publicado: (2017)

Pure Stage I Seminoma with an Elevated hCG of 25,265 mIU/ml: A Case Report
por: Katayama, Hiromichi, et al.
Publicado: (2016)

ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL
por: de OLIVEIRA, Valter Oberdan Borges, et al.
Publicado: (2016)

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml
por: Wu, Yingping, et al.
Publicado: (2021)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study
por: Huang, Xu, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Girls with Premature Thelarche Younger than 3 Years of Age May Have Stimulated Luteinizing Hormone Greater than 10 IU/L
por: Seymen Karabulut, Gülcan, et al.
Publicado: (2020)

Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis
por: Sadeghimehr, Maryam, et al.
Publicado: (2021)

Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL
por: Henrich, Timothy J., et al.
Publicado: (2012)

Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000–20000 IU/ml with ALT 1–2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT
por: Danis, Nilay, et al.
Publicado: (2021)

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment
por: Mihai, Florin, et al.
Publicado: (2021)

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response
por: Franco, Sandra, et al.
Publicado: (2023)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy
por: Arcaini, Luca, et al.
Publicado: (2012)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h3ju0itg0kh205qamqv1pp808d